Pazopanib Pazopanib (trade name Votrient) is a potent and selective multi-targeted receptor tyrosine kinase inhibitor that blocks tumour growth and inhibits angiogenesis. It has been approved for renal cell carcinoma and soft tissue sarcoma by numerous regulatory administrations worldwide It is a multikinase inhibitor, with c-KIT, FGFR, PDGFR and VEGFR being amongst the inhibited enzymes It is approved by numerous regulatory administrations worldwide (including the FDA (19 October 2009), EMA (14 June 2010), MHRA (14 June 2010) and TGA (30 June 2010)) for use as a treatment for advanced/metastatic renal cell carcinoma and advanced soft tissue sarcomas. In Australia it is subsidised under the PBS, under a number of conditions, including: The medication is used to treat clear cell variant renal cell carcinoma. The treatment phase is continuing treatment beyond 3-months. The patient has been issued an authority prescription for pazopanib The patient must have stable or responding disease according to the Response Evaluation Criteria In Solid Tumours (RECIST) This treatment must be the sole tyrosine kinase inhibitor subsidised for this condition. It has also demonstrated therapeutic properties in patients with ovarian and non-small cell lung cancer.
Posted on: Mon, 24 Mar 2014 20:55:47 +0000
Trending Topics
Recently Viewed Topics
© 2015